Like it or not, biologists have to deal increasingly in informatics as their experiments generate ever larger and more complex data sets. Few laboratories have the resources to develop their own ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing agreement today naming GenoSplice, Inc. as its preferred data analysis service provider for the new ...

Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...

The widely used Affymetrix Whole-Transcript Gene 1.0 ST (sense target) microarray platform, normally used to assay gene expression, can also be utilized to interrogate exon-specific splicing. A new ...

ExonHit Therapeutics has announced a supply and service provider agreement to combine Affymetrix' GeneChip® microarray platform and ExonHit's alternative RNA splicing technologies and expertise.

Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, No. 7 (Apr. 2, 2002), pp. 4379-4384 (6 pages) Microarray analysis of gene expression patterns for thousands of ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...

Thermo Fisher Scientific plans to buy Affymetrix for $1.3 billion, in a deal the buyer said will strengthen its position in bioscience research tools and genetic analysis. The deal, announced Friday ...

Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...